Shopping Cart
Remove All
Your shopping cart is currently empty
JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $4,859 | 8-10 weeks | 8-10 weeks |
| Description | JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy. |
| Targets&IC50 | αvβ5 integrin:6.3 nM, αvβ3 integrin:2.3 nM |
| Synonyms | JNJ26076713 |
| Molecular Weight | 490.64 |
| Formula | C29H38N4O3 |
| Cas No. | 669076-03-3 |
| Relative Density. | 1.31 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.